Surgery – Diagnostic testing – Detecting nuclear – electromagnetic – or ultrasonic radiation
Patent
1996-09-04
1999-02-23
Casler, Brian
Surgery
Diagnostic testing
Detecting nuclear, electromagnetic, or ultrasonic radiation
A61B 505
Patent
active
058738231
ABSTRACT:
A marker for use in screening patients for nervous system dysfunction and a method of producing the marker. The marker is a digital profile of a brain having a particular nervous system dysfunction that is used for screening patients for that nervous system dysfunction. The digital profile consists of a grid of values that are a numerical representation of graphical images of functional activity in the brain having that nervous systems dysfunction. The marker is produced by selecting a nervous system dysfunction and by creating a digital profile of predetermined functional activity at a plurality of sets of predetermined coordinates of a given brain geometry. The marker can also be used to screen patients for any specific functional brain activity not limited to nervous system dysfunctions.
REFERENCES:
patent: 4188956 (1980-02-01), John
patent: 4307726 (1981-12-01), Paulson et al.
patent: 4736751 (1988-04-01), Gevins et al.
patent: 4977896 (1990-12-01), Robinson et al.
patent: 5083571 (1992-01-01), Prichep
patent: 5215095 (1993-06-01), Macvicar et al.
patent: 5262945 (1993-11-01), DeCarli et al.
patent: 5269325 (1993-12-01), Robinson et al.
patent: 5299119 (1994-03-01), Kraf et al.
patent: 5302583 (1994-04-01), Costa et al.
patent: 5331969 (1994-07-01), Silberstein
patent: 5438989 (1995-08-01), Hochman et al.
patent: 5445937 (1995-08-01), Haley
Moeller, et al., "The Metabolic Topography of Normal Healthy Aging," Neurology, 44 (Supplement 2), p. A164, Apr. 1994.
Moeller, et al., "The Metabolic Topography of Normal Aging," Journal of Cerebral Blood Flow and Metabolism,", vol. 15 (Supplement 1), p. S593, Jul. 1995.
Moeller, et al., "The Metabolic Topography of Normal Aging,"Journal of Cerebral Blood Flow and Metabolism,",16 (No. 3), pp. 385-398, 1996.
Alexander, G.E. and J.R. Moeller, "Application of Scaled Subprofile Model Analysis to Functional Imaging of Neurological Disorders: A Principal Component Approach to Modeling Regional Patterns of Brain Function in Disease,"Human Brain Mapping, 2, pp. 79-94, 1994.
Eidelberg, et al., "Variability in Regional Cerebral Metabolic Rate for Glucose (rCMRGlu) and its Consequences for the Study of Neurological Disease with FDG/PET,"Neurology, 38 (Supplement 1), p. 367, Mar. 1988.
Eidelberg, et al., "The Metabolic Anatomy of Parkinson's Disease: emission tomographic studies," Movement disorders, 5(3), pp. 203-213, 1990.
Eidelberg, et al., "The Metabolic Pathology of Parkinson's Disease: Complementary 18F-Fluorodopa and 18F-Fluorodeoxyglucose PET Studies," 39(3), (Supplement 1), p. 273, Mar. 1989.
Eidelberg, et al., "The Metabolic Topography of Parkinsonism," J. Cereb. Blood Flow Metab., 14(5), Supplement 1, pp. 783-801, Sep. 1994.
Eidelberg, et al., "Brain Metabolic Topography In Parkinsonism," vol. 43(4), Supp. 2, Apr. 1993, p. A270.
Eidelberg, et al., "Brain Metabolic Topography in the Movement Disorders," Journal of Cerebral Blood Flow and Metabolism, vol. 13, (Supplement 1), p. S9, 1993.
Eidelberg , et al., "The Metabolic Topography of Idiopathic Torsion Dystonia," Brain, 118 (Pt. 6), pp. 1473-1484, 1995.
Eidelberg, et al., "Brain Metabolic Topography in Idiopathic Torsion Dystonia," vol. 43(4), (Supplement 2), P. A408, Apr. 1993.
Eidelberg, et al., "Early Differential Diagnosis of Parkinson's Disease with 18F-flourodeoxyglucose and positron emission tomography," Neurology, 45(11), pp. 1995-2004, Nov. 1995.
Eidelberg, et al., "Detection of Early Parkinson's Disease with 18-F Fluorodeoxyglucose and Positron Emission Tomography," Neurology, 44 (Supplement 2), p. A352, Apr. 1994.
Eidelberg, et al., "Detection of Early Parkinson's Disease with 18-F Fluorodeoxyglucose and Positron Emission Tomography," Journal of Nuclear Medicine, No. 31, 10P, 1994.
Eidelberg, et al., "Assessment of Disease Severity in Parkinsonism with fluorine-18-fluorodeoxyglucose and PET," Journal of Nuclear Medicine, 36(3), pp. 378-383, Mar. 1995.
Ishikawa, et al., "FDG/PET Predicts Clinical Disability in Parkinson's Disease," Neurology, 44.4 (Supplement 2), p. A280, May 1994.
Spetsieris, et al., "Visualizing the Evolution of Abnormal Metabolic Networks in the brain using PET," Comput. Med. Imaging Graph, 19(3), pp. 295-306, 1995.
Spetsieris, et al., "Visualizing Patterns of Neurological Disease Progression with PET," Physics of Medical Imaging, pp. 2168-2227, Feb. 1994.
Eidelberg David
Moeller James R.
LandOfFree
Markers for use in screening patients for nervous system dysfunc does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Markers for use in screening patients for nervous system dysfunc, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Markers for use in screening patients for nervous system dysfunc will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-301717